Adenocarcinoma of the pancreas is the fourth leading cause of cancer-related death in the United States. Therapeutic
responsiveness of pancreatic cancer to surgery, chemotherapy, and radiation therapy is poor, resulting in a dismal
5-year survival of less than 3%. Point mutation of the K-ras oncogene is a common event in the early development of
pancreatic cancer. Indeed, K-ras mutations occur in up to 95% of pancreatic cancers, with a resulting overall increase in
production of reactive oxygen species (ROS) through the activation of NADPH oxidase (NOX). Specifically, the extracellular
(non-mitochondrial) generation of superoxide (O2.-) from the NOX system results in cell growth and tumor progression.
Extracellular superoxide dismutase (SOD3, EcSOD) is the only isoform of superoxide dismutase (SOD) expressed
extracellularly. It modulates ROS by converting O2.- into hydrogen peroxide (H2O2). Antioxidant enzymes that scavenge
specific ROS have inhibited the in vitro and in vivo growth of pancreatic cancer. It has been demonstrated that overexpression
of EcSOD inhibits pancreatic cancer cell growth and intracellular signaling pathways. Therefore, we propose that
strategies to scavenge non-mitochondrial-generated superoxide may prove beneficial in the treatment pancreatic cancer.
This review will focus on the role of O2.- as a pro-tumorigenic signaling molecule, including its generation and hypothesized
mechanism of action, as well as the role of EcSOD in inhibiting tumor growth and propagation, and its potential as a
targeted pancreatic cancer therapy.
Superoxide, pancreatic cancer, superoxide dismutase, hypoxia-inducible factor-1α.
1528 JCP, 200 Hawkins Drive, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.